Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

82 results about "Brain Thrombus" patented technology

Brain-targeted stem cell membrane bionic cationic liposome as well as preparation method and application thereof

The invention discloses brain-targeted stem cell membrane bionic cationic liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: extracting and purifying to obtain a stem cell membrane; preparing a cationic liposome; the stem cell membrane and the cationic liposome are fused to obtain the stem cell membrane bionic cationic liposome, and the relative dosage of the stem cell membrane and the cationic liposome is that the mass ratio of the total protein mass of the stem cell membrane to the total fat mass of the cationic liposome is 1: (2-24). The stem cell membrane bionic cationic liposome constructed by using the purified stem cell membrane has high brain targeting ability, low immune irritation and efficient nucleic acid drug carrying ability, can break through the blood brain barrier, realizes efficient targeting delivery of nucleic acid drugs to cells of the brain including neurons, and has good application prospects. Particularly, the polypeptide can be used as a targeted delivery platform of nucleic acid drugs for targeted therapy of cerebral diseases, especially cerebral arterial thrombosis.
Owner:ZHEJIANG UNIV

Thrombolysis prediction method based on deep learning and multi-modal fusion

The invention discloses a thrombolysis prediction method based on deep learning and multi-modal fusion, and belongs to the technical field of thrombolysis prediction, and the method comprises the steps: S1, collecting an MRI image of a patient with ischemic cerebral apoplexy, and constructing a cerebral apoplexy automatic segmentation model; s2, carrying out image registration; s3, lesion segmentation; and S4, thrombolysis prediction. According to the cerebral apoplexy automatic segmentation model based on the gating parallel Mama network, the long-distance dependency relationship in the image can be effectively captured, ischemic cerebral apoplexy lesions can be rapidly and accurately segmented, and the lesion identification efficiency and accuracy are greatly improved; according to the algorithm provided by the invention, the linear time complexity is realized, the computing resource consumption is greatly reduced, and the bottleneck of the prior art is broken through; according to the cerebral apoplexy thrombolysis prediction model based on the multi-modal data, scientific automatic decision support is provided for judging whether the patient is suitable for thrombolysis treatment or not, and the quality and safety of medical decision are improved.
Owner:TIANJIN UNIV

Application of targeted liposome as active ingredient in preparation of medicine for treating ischemic brain injury

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.
Owner:CHENGDU MEDICAL COLLEGE

Brain-targeted nano preparation loaded with ergosterol as well as preparation method and application of brain-targeted nano preparation

The invention provides an ergosterol-loaded brain-targeted nano preparation and a preparation method and application thereof, and relates to the field of nano materials and nano biological medicine.The active ingredient ergosterol of the nano preparation is entrapped in a DSPE-PEG-pinacol borate nano material, and the nano material has the ROS response characteristic and can be used for preparing a brain-targeted nano preparation. The ergosterol-loaded nano preparation is in the shape of a regular sphere, is uniform in particle size, has good dispersibility and stability, has good ability of targeted therapy of cerebral arterial thrombosis diseases, effectively solves the problems of poor targeting property, low bioavailability and the like of common drugs, enhances the therapeutic effect of ergosterol on cerebral arterial thrombosis, and has good application prospects. The ergosterol can effectively improve brain injury caused by the cerebral arterial thrombosis and has a good treatment effect, meanwhile, the ergosterol serving as the active ingredient plays a role in treating the cerebral arterial thrombosis by activating a PI3K / AKT / mTOR pathway, and a new direction is provided for treatment of the cerebral arterial thrombosis.
Owner:XUZHOU KEJIYUAN BIOTECHNOLOGY CO LTD

Photo-thermal nano-drug containing guanidyl structure as well as preparation method and application of photo-thermal nano-drug

The invention belongs to the technical field of biomedical materials, and particularly relates to a photothermal nano-drug containing a guanidyl structure as well as a preparation method and application of the photothermal nano-drug, and the photothermal nano-drug is CA-COFBT-TG (at) TS obtained by taking COFBT-TG containing guanidyl as a carrier, loading a photothermal agent TS and then modifying a fibrin targeting peptide CA on the surface. The photo-thermal nano-drug is a covalent organic framework material platform, can be enriched at a thrombus part, has excellent photo-thermal conversion performance, can effectively remove thrombus at a focus part, and can improve neuronal death after cerebral arterial thrombosis by inhibiting ferroptosis.
Owner:THE SECOND AFFILIATED HOSPITAL TO NANCHANG UNIV

Pediococcus acidilactici and application thereof in improving cerebral apoplexy, fatty liver and uric acid metabolism

ActiveCN118995541ABacteriaDigestive systemAlcohol degradationXanthine
The invention discloses pediococcus acidilactici and application thereof in improving cerebral apoplexy, fatty liver and uric acid metabolism, and belongs to the technical field of marine microorganisms. The pediococcus acidilactici NHNK-610 is preserved in the China Center for Type Culture Collection on April 25, 2024, and the preservation number of the pediococcus acidilactici NHNK-610 is CCTCC (China Center for Type Culture Collection) NO: M2024797. Experiments show; the NHNK-610 has the effects of dissolving thrombus, regulating blood coagulation factors of vascular endothelial cells, repairing aged blood vessels, promoting blood brain barriers, inhibiting Klebsiella pneumonia from generating alcohol, agglutinating Klebsiella pneumonia, inhibiting virulence genes of Klebsiella pneumonia, promoting alcohol metabolism, reducing alcohol damage, resisting alcohol, degrading uric acid, inhibiting xanthine oxidase activity, and inhibiting the activity of Klebsiella pneumonia. Uric acid excretion is promoted, and the function of colonization of mucoprotein and intestinal epithelial cells is improved through a thallus biological membrane.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Fusion model and method of cerebral arterial thrombosis multi-sequence magnetic resonance images

The invention relates to a fusion model and method of cerebral arterial thrombosis multi-sequence magnetic resonance images. The invention discloses a fusion model of cerebral arterial thrombosis multi-sequence magnetic resonance images. The fusion model comprises a focus detection module, two progressive feature guide modules, an edge detection module and a loss function module, the focus detection module is used for focusing on a high-signal focus area in the DWI image; the progressive feature guiding module is used for guiding modal image branches to perform feature extraction; the edge detection module is used for extracting lesion edge features. The cerebral arterial thrombosis multi-sequence magnetic resonance image fusion model and the cerebral arterial thrombosis multi-sequence magnetic resonance image fusion method not only achieve SOTA on objective indexes, but also have more explanatory subjective fusion effects, achieve unification of subjective and objective evaluation of cerebral arterial thrombosis auxiliary diagnosis for the first time, and improve the accuracy of cerebral arterial thrombosis auxiliary diagnosis. The clinical problem in cerebral arterial thrombosis multi-sequence magnetic resonance image fusion is effectively solved.
Owner:XINJIANG UNIVERSITY +1

Neuron protection and function recovery method after focal cerebral arterial thrombosis

The invention relates to a neuronal protection and function recovery method and a verification experiment method after focal cerebral arterial thrombosis, and the neuronal protection and function recovery method is characterized in that nerve injury is inhibited by regulating miR-212-5p / PLXNA2 so as to promote nerve protection and function recovery after cerebral arterial thrombosis injury.
Owner:THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE

Application of polypeptide in preparation of medicine for preventing or treating cerebral apoplexy

The invention discloses an application of a polypeptide in preparation of a medicine for preventing or treating cerebral apoplexy. The polypeptide comprises an amino acid sequence as shown in SEQ ID NO: 1. The N15 polypeptide expressed by the sequence can inhibit apoptosis and autophagy of damaged neurons by inhibiting expression of Tom20 and PARP proteins, promote expression of SYN-1 protein to promote a patient with ischemic cerebral apoplexy to recover learning, memory and cognitive functions, can comprehensively protect neuronal damage caused by ischemic cerebral apoplexy, can promote recovery of damaged nerve cells of an OGD model, and has a good application prospect. The polypeptide has an obvious protection effect on neuronal cells, the polypeptide is connected with a cell transmembrane carrier and can penetrate through a blood brain barrier to enter brain tissue to directly act on the neuronal cells, and an ischemic cerebral apoplexy animal model verifies that the polypeptide has an effect of treating cerebral apoplexy. Particularly, the cognitive ability and learning and memory ability of a mouse with cerebral arterial thrombosis can be recovered to a normal level, and a good treatment effect on cerebral arterial thrombosis is achieved.
Owner:WUHAN YICHENG BIOTECH CO LTD

Multifunctional bionic nanoparticle with enzyme as targeting function motif and preparation method and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a multifunctional bionic nanoparticle with enzyme as a targeting function motif and a preparation method and application thereof. According to the preparation method disclosed by the invention, cell membrane-coated drug-loaded dopamine nanoparticles are obtained through synthesis of a PDA nanoparticle solution, drug loading, membrane coating and reaction of biotin-modified enzyme and streptavidin, and the membrane-coated drug-loaded dopamine nanoparticles are high in compatibility, good in stability and suitable for selective delivery of hydrophobic drugs; the medicine can be effectively delivered to a focus part, so that the circulation time of enzyme is prolonged, the activity of the enzyme in a body is protected, oxidative stress is relieved, and the medicine concentration of the focus part is improved; the traditional Chinese medicine composition can effectively regulate cerebral arterial thrombosis neurovascular units, degrade NETs, relieve oxidative stress, improve neuron activity and inhibit glial cell activation.
Owner:FUDAN UNIVERSITY

Application of radix astragali seu hedysari glucoside in treatment of cerebral arterial thrombosis

The invention discloses an application of astragaloside in treatment of cerebral arterial thrombosis, belongs to the technical field of biological medicines, and observes M2 polarization of astragaloside on glial cells in cerebral arterial thrombosis and neuroinflammation regulation effects of astragaloside on the glial cells in cerebral arterial thrombosis through a PPAR gamma signal channel by utilizing a middle cerebral artery embolism rat model. It is clear that astragaloside has a neuroprotective effect on rats after cerebral arterial thrombosis, microglial cells are promoted to be transformed into M2 type by activating a PPAR gamma signal channel, and prognosis of cerebral arterial thrombosis is improved. It is proved that astragaloside has further development value in the aspect of prevention and treatment of cerebral arterial thrombosis, and the astragaloside has the prospect of becoming an ideal medicine for preventing and treating cerebral arterial thrombosis.
Owner:XINJIANG UYGUR AUTONOMOUS REGION OCCUPATIONAL DISEASE HOSPITAL (XINJIANG UYGUR AUTONOMOUS REGION OCCUPATIONAL DISEASE PREVENTION & CONTROL HOSPITAL)

Cerium oxide nano-enzyme delivery system based on carried neutrophil

The invention relates to the technical field of biological medicine, in particular to a cerium oxide nano-enzyme delivery system based on carried neutrophil, and the system comprises cerium oxide nano-particles; the surfaces of the cerium oxide nanoparticles are coated with the lipoic acid zwitterionic polymer layers; the sialic acid molecules and the protocatechuic aldehyde molecules are modified on the surface of the lipoic acid zwitterionic polymer layer; wherein the system realizes breakthrough of a blood brain barrier and precise delivery of ischemic lesions through mediation targeting delivery of L-selectin on the surface of neutrophile granulocyte, and based on a cerium oxide nano-enzyme delivery system carrying neutrophile granulocyte, a'antioxidation-anti-inflammation-angiogenesis promotion-neural restoration 'quadruple synergistic mechanism is integrated, so that the system has the advantages that the system is simple in structure and convenient to use, and the application prospect is wide. And a new strategy of multi-target intervention is provided for cerebral arterial thrombosis treatment.
Owner:JILIN UNIVERSITY

New application of gastrodin

The invention provides novel application of gastrodin, and belongs to the technical field of biological medicine. By constructing an MCAO model of cerebral arterial thrombosis and detecting the influence of GAS on MCAO mouse and OGD-induced microglial cell ferroptosis, it is found that GAS alleviates the ferroptosis of cerebral arterial thrombosis, it is found through molecular docking and cell thermal displacement experiments that GAS is specifically bound with Alkbh5, the stability of protein is improved, nuclear translocation of Alkbh5 is promoted, and the GAS can be used for treating cerebral arterial thrombosis. Therefore, the methylation level of N6-methyladenosine (m6A) of a glutamic acid-cysteine ligase modified subunit (Gclm) is reduced, the expression of the Gclm is increased, the synthesis of glutathione is enhanced, and finally ferroptosis of microglial cells is inhibited. Therefore, the gastrodin can be used for preparing the medicine for treating the ferroptosis of the cerebral arterial thrombosis, and a new natural medicine source is provided for preventing and treating the ferroptosis of the cerebral arterial thrombosis.
Owner:KUNMING MEDICAL UNIVERSITY

Application of Bremelinan in preparation of medicine for treating cerebral arterial thrombosis

InactiveCN119074890Areduce areaImprove rate of improvementNervous disorderCyclic peptide ingredientsPharmaceutical drugBehavioral dysfunction
The invention belongs to the technical field of medicines, and particularly relates to application of Bramer's olantin in preparation of a medicine for treating cerebral arterial thrombosis. The invention provides a new medicinal application of Bremelinodan, namely an application of Bremelinodan in preparation of a medicine for preventing and / or treating cerebral arterial thrombosis. Research finds that the Bramer's olantoin can effectively improve behavioral dysfunction, significantly reduce the cerebral infarction area and improve the cerebral infarction improvement rate, and presents dose correlation, which indicates that the Bramer's olantoin has a neuroprotective effect on cerebral arterial thrombosis and proves that the Bramer's olantoin can be used as a medicine for treating cerebral arterial thrombosis.
Owner:ZHEJIANG WANBANG PHARMA

Use of mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection

PCT designated stageWO2025162163A1Cell dissociation methodsNervous disorderTissue CompatibilityParticle-size distribution
Disclosed in the present invention is the use of a mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection. Compared to a small extracellular vesicle with exosomes as the main component, the small intracellular nanovesicle of the present invention has a smaller particle size, a narrower particle size distribution range, and greater stability at different temperatures, and has good tissue compatibility. The small intracellular nanovesicle of the present invention can better ameliorate nerve injury or neurodegenerative diseases such as optic nerve injury, ischemic stroke and Alzheimer's disease, and has very good application and research value in the field of pharmaceuticals.
Owner:TIANJIN MEDICAL UNIVERSITY EYE HOSPITAL

Application of DP-b99 and derivative thereof in preparation of medicine for treating cerebral ischemia mechanical thrombectomy reperfusion injury

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.
Owner:XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI

Self-assembled nano preparation coated with macrophage membrane as well as preparation method and application of self-assembled nano preparation

The invention belongs to the technical field of biological medicines, and particularly discloses a self-assembled nano preparation coated with a macrophage membrane as well as a preparation method and application of the self-assembled nano preparation. According to the nano preparation, nano particles formed by self-assembly of epigallocatechin gallate (EGCG), ferric chloride (FeCl3) and edaravone (EDV) serve as a core, and the outer layer of the nano preparation is coated with a macrophage membrane. The preparation method is a one-pot method and comprises the following steps: mixing and self-assembling EGCG, FeCl3 and EDV in a phosphate buffer solution, carrying out centrifugal purification, and carrying out ultrasonic fusion with a macrophage membrane. The nano preparation is uniform in particle size, has excellent free radical scavenging capacity and antioxidant activity, can effectively pass through a blood-brain barrier and target a cerebral ischemia reperfusion injury area, and shows a remarkable effect in preparation of drugs for treating cerebral arterial thrombosis.
Owner:SUN YAT SEN UNIV +1

Stem cell modified with flexible anti-oxidative stress coating as well as preparation method and application of stem cell

The invention discloses a stem cell modified with a flexible anti-oxidative stress coating as well as a preparation method and application of the stem cell, and relates to the technical field of stem cell treatment. The stem cells with the anti-oxidative stress function are obtained, the targeting capacity of the stem cells is not affected, and the deformability of the stem cells is remarkably enhanced. The obtained stem cells with the anti-oxidative stress function can be applied to treatment of cerebral diseases such as cerebral arterial thrombosis. According to the preparation method disclosed by the invention, on the premise of not changing the targeting capability and mechanical property of the stem cells, the resistance of the stem cells to a high oxidative stress disease microenvironment of cerebral diseases such as cerebral arterial thrombosis is improved.
Owner:ZHEJIANG UNIV +1

Nano preparation capable of being used for cerebral arterial thrombosis gene drug targeted delivery

The invention relates to the technical field of fusion membrane nano preparations, and provides a nano preparation capable of being used for cerebral arterial thrombosis gene drug targeted delivery, which comprises lipid-calcium phosphate nanoparticles, which are composed of DOPA modified calcium phosphate cores and lipidosome and are used for providing positive charges to obtain efficient gene loading efficiency and proton sponge effect, the intracellular efficient delivery and release of the gene are realized; and the exosome membrane is prepared from a cell culture solution extracted from bone marrow-derived mesenchymal stem cells and is used for improving the transfection efficiency of the carried medicine. According to the present invention, by using the process characteristic that the inner layer phospholipid and the outer layer phospholipid are not synchronously prepared during the LCP preparation process, the biological membrane of the exosome and the LCP outer layer phospholipid are fused during the LCP preparation of the outer layer phospholipid so as to construct the fusion membrane preparation having the characteristics of the biological membrane and capable of carrying out AMD3100 targeting modification, such that the advantages of the biological membrane and the AMD3100 in the targeting delivery system are combined so as to achieve the target delivery effect; and the bottleneck of drug delivery for brain diseases is solved.
Owner:FUDAN UNIVERSITY +1

Quantitative method and device for water content ratio, tomography system and storage medium

PendingCN121287178AComputerised tomographsTomographyBrain edemaVoxel
The invention provides a method for quantifying a water content ratio, which comprises the following steps of: scanning a brain by using first energy and second energy through dual-energy CT (Computed Tomography) equipment to generate plain scanning data of each voxel; setting the three substances of the dual-energy tomography three-substance separation mathematical model as water, grey matter and white matter; processing the plain scanning data of each voxel by using the dual-energy tomography three-substance separation mathematical model to obtain enhanced data of each voxel; and calculating the water content percentage of each voxel according to the enhancement data of each voxel. The method for quantifying the water content can quantify the water content of the encephaledema tissue of the acute stroke patient, and further quantify the edema proportion of the encephaledema tissue. The invention further provides a water content ratio quantifying device, a tomography system and a storage medium which relate to the method.
Owner:SIEMENS HEALTHINEERS DIGITAL TECH (SHANGHAI) CO LTD

Selective KCNQ channel opener and application thereof in pharmacy

The invention provides a selective KCNQ channel opener and application of the selective KCNQ channel opener in pharmacy. According to the invention, a series of KCNQ channel openers with high selectivity are obtained by carrying out structural modification and activity and selectivity evaluation on a KCNQ2 agonist 124-A10 (CAS number: 1173735-00-6) obtained by screening. Compared with common KCNQ channel openers, such as retigabine, ICA27243 and the like, the subtype selectivity of the compounds is enhanced, so that some toxic and side effects generated in the application of pharmaceutical preparations due to poor selectivity can be effectively avoided. The invention also provides applications of the compounds in preparation of anti-epileptic drugs, anti-schizophrenia drugs, anti-depression drugs and drugs for treating cerebral arterial thrombosis diseases, and provides more effective choices for treatment of related diseases.
Owner:HEBEI MEDICAL UNIVERSITY

Application of peroxide reductase 1 as target spot in preparation of IS treatment medicine

The invention relates to application of peroxidase reductase 1 as a target spot in preparation of an IS treatment medicine, and belongs to the technical field of biological medicine. The method comprises the steps of high-sensitivity blood immune proteome map construction, large-scale independent queue longitudinal correlation verification, cross-racial and multi-tissue causal correlation verification, targeted experiment verification and mechanism exploration, target druggability evaluation, treatment potential confirmation and the like, and selects immune response proteins with significant differences between patients and controls. The immune response protein strongly related to the onset risk of the cerebral arterial thrombosis (IS) is further screened from plasma, cerebrospinal fluid and brain tissue samples, and finally the cerebral arterial thrombosis traditional Chinese medicine target peroxide reductase 1 (PRDX1) is found. A drug, such as a PRDX1 agonist or overexpression PRDX1, designed aiming at the drug target can effectively improve the progress of the IS disease.
Owner:NINGBO INST OF LIFE & HEALTH IND UNIV OF CHINESE ACAD OF SCI

Application of lncRNA-AU020206 in preparation of medicine for treating cerebral arterial thrombosis

The invention belongs to the technical field of gene drugs, and particularly relates to application of lncRNA-AU020206 in preparation of drugs for treating cerebral arterial thrombosis, the key effect of the lncRNA-AU020206 in occurrence and development of the cerebral arterial thrombosis is disclosed for the first time, and it is clear that the lncRNA-AU020206 activates ferroptosis signal channels through negative regulation of SLC7A11 expression, so that cerebral ischemia reperfusion injury is aggravated. In-vivo and in-vitro experiments prove that the levels of MDA, ROS and Fe < 2 + > can be remarkably reduced by silencing the lncRNA-AU020206, the expression of GPX4 and SLC7A11 can be up-regulated, the cerebral infarction volume and neurological dysfunction can be reduced, and cerebral edema and apoptosis can be improved. Therefore, the lncRNA-AU020206 not only can be used as a new target for treating the cerebral arterial thrombosis, but also can be used for developing a related diagnostic kit, and has remarkable clinical application prospect and market value.
Owner:GUANGDONG MINGZHU BIOTECHNOLOGY CO LTD

Application of Nrsn1 in preparation of medicine for differentiating neural stem cells into neuronal cells

The invention discloses application of Nrsn1 in preparation of a medicine for differentiating neural stem cells into neuronal cells, and belongs to the technical field of neurobiology. The invention provides application of Nrsn1 in preparation of a medicine for differentiating neural stem cells into neuronal cells. The invention relates to application of Nrsn1 in preparation of drugs for preventing and / or treating cerebral arterial thrombosis or neurodegenerative diseases. It is found that the Nrsn1 gene can promote the neural stem cells to be differentiated into neurons, and the efficiency of differentiating the neural stem cells into the neurons is improved.
Owner:TAIHE HOSPITAL OF SHIYAN CITY (AFFILIATED HOSPITAL OF HUBEI UNIVERSITY OF MEDECINE)

Application of Mbtps1 gene and protein SKI-1 coded by Mbtps1 gene in screening or preparing medicine for treating cerebral arterial thrombosis

The invention discloses an application of an Mbtps1 gene and a protein SKI-1 coded by the Mbtps1 gene in screening or preparing a medicine for treating cerebral arterial thrombosis, and particularly discloses an application of the Mbtps1 gene / protein SKI-1 as a medicine target of cerebral arterial thrombosis. A tMCAO mouse model is constructed by specifically knocking out a microglial cell Mbtps1 gene / protein SKI-1 of a tMCAO mouse to verify that the Mbtps1 gene and the protein SKI-1 can be used as drug targets for screening or preparing drugs for treating cerebral arterial thrombosis; the compound PF429242 is screened out and has the functions of repairing brain injury nerves caused by cerebral arterial thrombosis, inhibiting neuroinflammation and repairing fragmentation of a mitochondrial network, namely, the feasibility of the Mbtps1 gene and the protein SKI-1 serving as targets in screening or preparing medicines for preventing or treating cerebral arterial thrombosis is verified.
Owner:XUZHOU MEDICAL UNIVERSITY

Application of Ptbp2 in diagnosis and prognosis of cerebral arterial thrombosis

The invention discloses application of Ptbp2 in diagnosis and prognosis of cerebral arterial thrombosis. It is found for the first time that Ptbp2 can be used for early diagnosis of cerebral arterial thrombosis, and the Ptbp2 also has a good prediction effect on prognosis of cerebral arterial thrombosis patients. According to the present invention, the verification results of the collected real clinical samples show that the Ptbp2 has good effects of cerebral arterial thrombosis diagnosis and prognosis prediction, and has high accuracy, high sensitivity and high specificity. The invention provides a new thought and strategy for the technical field of cerebral arterial thrombosis diagnosis and prognosis prediction, and has important scientific significance and clinical application value.
Owner:THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV

A brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method and uses

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.
Owner:JIANGSU PROVINCIAL HOSPITAL OF TCM

Kit for screening cerebral arterial thrombosis risk and screening method

The invention discloses a kit for screening cerebral arterial thrombosis risk and a screening method, and belongs to the technical field of biological detection. The kit for screening the cerebral arterial thrombosis risk is a kit for detecting gene mutation of a C677T site of an MTHFR gene and comprises a forward primer and a reverse primer, the sequence of the forward primer is shown as SEQ ID NO.1, and the sequence of the reverse primer is shown as SEQ ID NO.2. The kit for screening the cerebral arterial thrombosis risk is a kit for detecting gene mutation of the C677T site of the MTHFR gene. The invention creatively finds that the gene polymorphism of the C677T site of the MTHFR gene has certain relevance with the disease of the cerebral arterial thrombosis, the site mutation is one of high-risk factors of the cerebral arterial thrombosis, and the A1298C site mutation of the MTHFR gene is not obviously associated with the susceptibility of the cerebral arterial thrombosis. The risk of the cerebral arterial thrombosis is evaluated by screening a susceptibility gene locus, the operation is simple, the cost is reduced, the prevention of the cerebral arterial thrombosis is enhanced, and the incidence rate of the cerebral arterial thrombosis is further reduced.
Owner:LIAOCHENG PEOPLES HOSPITAL

Application of ShSPI in preparation of medicine for treating or preventing thrombosis diseases

The invention belongs to the field of novel pharmaceutical application of functional peptides, and particularly relates to application of ShSPI in preparation of drugs for treating or preventing thrombosis diseases. The centipede-derived polypeptide ShSPI disclosed by the invention is free from any toxic and side effects and high in biological safety; experiments prove that ShSPI has the effects of resisting thrombus, resisting platelets and treating cerebral arterial thrombosis, is low in action concentration and high in activity, and can be used for preparing medicines for treating or preventing thrombus diseases and medicines related to anticoagulation.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI